Glenmark Launches BRUKINSA in India for B-Cell Cancers

  Published 10 months ago

Glenmark launches BRUKINSA, India's first BTK inhibitor for five B-cell cancers approved by DCGI with global trials and lower cardiac risks.

  • Treats CLL/SLL, WM, MCL, MZL, FL with proven efficacy and safety from ALPINE, ASPEN, SEQUOIA trials.
  • Addresses India's blood cancer burden with high response rates and flexible dosing for personalized care.
  • Shows 1.9% vs. 7.7% serious cardiac events vs. ibrutinib in relapsed/refractory CLL studies.

You might like these

Uranium Stocks Surge on Nuclear Deal

Adani Ports Launches $450M Buyback

GTPL Q1 Revenue Up, EBITDA Down

Paytm Postpaid: Instant UPI Credit Line

Groww Raises Minimum Brokerage: What Investors Need to Know

GAIL Signs 10-Year LNG Deal with Vitol

India Bond Yields Dip Amid Rate Cut Expectations

News that matters the most ⚡